Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Felix, Ashley S ^a   Stone, Roslyn A ^b   Chivukula, Mamatha ^c   Bowser, Robert ^d   Parwani, Anil V ^d   Linkov, Faina ^b,e   Edwards, Robert P ^f   Weissfeld, Joel L ^b,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

chemokines; clear cell; metastasis; papillary serous; prognostic biomarkers

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; ESTROGEN RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TUMOR VOLUME;

CHEMOKINE CXCL12; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84861651897     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27317     Document Type: Article

References (36)

1. Mendivil A, Schuler KM, Gehrig PA,. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009; 16: 46-52.
2. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM,. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol 2010; 116: 10-4.
3. Hidaka T, Kato K, Yonezawa R, Shima T, Nakashima A, Nagira K, Nakamura T, Saito S,. Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol 2007; 33: 86-90.
4. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR, Oliva E,. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007; 31: 979-87.
5. Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C, Verkooijen HM,. Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol 2008; 29: 57-60.
6. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK,. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94: 642-6.
7. Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR,. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys 2002; 54: 79-85.
8. Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, Lu KH,. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res 2003; 63): 6195-9.
9. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB,. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008; 199: 543 e1- e7.
10. Balkwill F,. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50.
11. Ben-Baruch A,. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008; 25: 345-56.
12. Zlotnik A,. Chemokines in neoplastic progression. Semin Cancer Biol 2004; 14: 181-5.
13. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
14. Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK, Menger MD,. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007; 9: 862-70.
15. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F,. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008; 122: 91-9.
16. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N, Imamura M,. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000; 6: 3530-5.
17. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, Pfeffer U,. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 2009; 45: 2579-87.
18. Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O,. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 2010; 123: 733-45.
19. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O, Basik M,. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 2009; 175: 66-73.
20. Ruiz A, Salvo VA, Ruiz LA, Baez P, Garcia M, Flores I,. Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis. Reprod Sci 2010; 17: 894-903.
21. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M, Orlando C,. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 2009; 26: 261-8.
22. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS, Friese K,. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 2005; 25: 1679-86.
23. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A,. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009; 69: 5793-800.
24. Zhao D, Li XP, Gao M, Zhao C, Wang JL, Wei LH,. Stromal cell-derived factor 1alpha stimulates human endometrial carcinoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt. Gynecol Oncol 2006; 103: 932-7.
25. Kubarek L, Jagodzinski PP,. Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett 2007; 581: 1441-8.
26. Kodama J, Hasengaowa Seki N, Kusumoto T, Hiramatsu Y,. Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol 2007; 28: 370-5.
27. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F,. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010; 21: 1851-6.
28. Hodi Z, Chakrabarti J, Lee AH, Ronan JE, Elston CW, Cheung KL, Robertson JF, Ellis IO,. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol 2007; 60: 299-302.
29. Teicher BA, Fricker SP,. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
30. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB,. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006; 25: 4986-97.
31. Wendt MK, Cooper AN, Dwinell MB,. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 2008; 27: 1461-71.
32. Mizokami Y, Kajiyama H, Shibata K, Ino K, Kikkawa F, Mizutani S,. Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. Int J Cancer 2004; 110: 652-9.
33. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F,. Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clin Exp Metastasis 2007; 24: 423-9.
34. Fujimoto J Sato E,. Clinical implication of estrogen-related receptor (ERR) expression in uterine endometrial cancers. J Steroid Biochem Mol Biol 2009; 116: 71-5.
35. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, Wang H,. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2598-604.
36. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S,. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 2009; 132: 202-10.